| Zeit | Aktuelle Nachrichten
Sprache: | | Leser | Medien |
|---|
| 22.05. | Amarin Receive Patent Allowance for Combination Product of Vascepa and Statin Therapy | | 2 | Benzinga.com |
| 20.05. | Vascepa Data Should Make Amarin Longs Worried | | 3 | Seeking Alpha |
| 20.05. | Amarin: It's The Strategy, Not The Science | | 1 | Seeking Alpha |
| 15.05. | Amarin & Celsion: Post-Earnings Roundup | | 22 | Seeking Alpha |
| 14.05. | Buyers Accumulate Shares of Amarin, Up 4.7% | | 11 | SmarTrend |
| 14.05. | Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground | | 7 | Seeking Alpha |
| 10.05. | Amarin rises on 1Q report of Vascepa sales | | 6 | Yahoo-USA |
| 10.05. | Shares of Amarin Receive a Boost, Up 5.1% | | 3 | SmarTrend |
| 10.05. | Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin | | 11 | The Street |
| 10.05. | Risky Amarin Sets Its Cash Pile On Fire | | 6 | Seeking Alpha |
| 10.05. | Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcript | | 3 | Seeking Alpha |
| 09.05. | Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits | | 3 | The Street |
| 09.05. | 26.1% Return Seen to Date on SmarTrend Amarin Call | | 2 | SmarTrend |
| 06.05. | Can Amarin Make Me A Believer This Thursday? | | 5 | Seeking Alpha |
| 01.05. | Amarin Shares Down 23.7% Since SmarTrend's Sell Call | | 3 | SmarTrend |
| 01.05. | Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa) | | 9 | Seeking Alpha |
| 30.04. | AMARIN CORP PLC\UK - 8-K, Current Report | | 2 | SEC Filings |
| 30.04. | Amarin (AMRN) Receives FDA Approval for BASF sNDA as Vascepa API | | 8 | StreetInsider.com |
| 29.04. | Amarin's Performance Issues: Here To Stay? | | 6 | Seeking Alpha |
| 24.04. | Amarin: The Losing Streak Continues | | 7 | SmarTrend |
